Skip to Content

Ruxolitinib Extended Release (Jakafi XR) for the Management of Myelofibrosis (MF), Polycythemia Vera (PV), and Graft-Versus-Host Disease (GVHD)

Download PQI pdf

Last Updated: October 21, 2026

By: Nicole Bentivegna, PharmD, BCOP

About this PQI

This document provides guidance on the safe use, monitoring, and adverse event management associated with ruxolitinib extended release in its approved indications.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI